×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
合肥物质科学研究院 [7]
自动化研究所 [3]
厦门大学 [2]
西安交通大学 [1]
金属研究所 [1]
中南大学 [1]
更多...
内容类型
期刊论文 [15]
会议论文 [1]
发表日期
2022 [4]
2021 [2]
2020 [2]
2019 [1]
2018 [1]
2017 [1]
更多...
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共16条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:
Li, Ning
;
Zhang, Youzhong
;
Wang, Jing
;
Zhu, Jianqing
;
Wang, Li
收藏
  |  
浏览/下载:27/0
  |  
提交时间:2022/12/22
Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR)
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:
Jin, Jing
;
Tang, Yuan
;
Hu, Chen
;
Jiang, Li-Ming
;
Jiang, Jun
收藏
  |  
浏览/下载:21/0
  |  
提交时间:2022/12/23
Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial
期刊论文
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022
作者:
Liu, Jihong
;
Yin, Rutie
;
Wu, Lingying
;
Zhu, Jianqing
;
Lou, Ge
收藏
  |  
浏览/下载:31/0
  |  
提交时间:2022/05/05
BRCA mutation
China
olaparib
ovarian cancer
PARP inhibitor
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
期刊论文
LANCET ONCOLOGY, 2022, 卷号: 23
作者:
Zhou, Qing
;
Chen, Ming
;
Jiang, Ou
;
Pan, Yi
;
Hu, Desheng
收藏
  |  
浏览/下载:104/0
  |  
提交时间:2022/03/21
Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy
期刊论文
EUROPEAN JOURNAL OF RADIOLOGY, 2021, 卷号: 142, 页码: 8
作者:
Wei, Shengcai
;
Han, Yuqi
;
Zeng, Hanjiang
;
Ye, Shuai
;
Cheng, Jin
收藏
  |  
浏览/下载:69/0
  |  
提交时间:2021/11/03
Histopathologic growth pattern
Colorectal liver metastases
Unresectable
Radiomics
Bevacizumab
Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study
期刊论文
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 卷号: 9
作者:
Shen, Xia-Bo
;
Li, Guang-Liang
;
Zheng, Ya-Bing
;
Chen, Zhan-Hong
;
Cao, Wen-Ming
收藏
  |  
浏览/下载:23/0
  |  
提交时间:2021/11/01
Advanced breast cancer (ABC)
aromatase inhibitors (AIs)
everolimus (EVE)
fulvestrant (FUL)
retrospective study
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients
期刊论文
PLOS ONE, 2020, 卷号: 15
作者:
Ding, Yuqin
;
Ding, Kaijing
;
Yang, Hongjian
;
He, Xiangming
;
Mo, Wenju
收藏
  |  
浏览/下载:23/0
  |  
提交时间:2020/11/26
CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study
期刊论文
FRONTIERS IN ONCOLOGY, 2020, 卷号: 10, 页码: 9
作者:
Li, Hailin
收藏
  |  
浏览/下载:48/0
  |  
提交时间:2020/04/07
computed tomography
radiomics
non-small-cell lung cancer
tyrosine kinase inhibitor resistance
anaplastic lymphoma kinase
Association between Chinese Medicine Therapy and Survival Outcomes in Postoperative Patients with NSCLC: A Multicenter, Prospective, Cohort Study
期刊论文
CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2019, 卷号: 25
作者:
收藏
  |  
浏览/下载:10/0
  |  
提交时间:2020/10/26
CELL LUNG-CANCER
ADJUVANT CHEMOTHERAPY
Chinese medicine
non-small cell lung cancer
postoperative care
cohort study
disease-free survival
Turning a Luffa Protein into a Self-Assembled Biodegradable Nanoplatform for Multitargeted Cancer Therapy.
期刊论文
ACS nano, 2018, 卷号: 12, 页码: 11664-11677
作者:
He Wangxiao
;
Yan Jin
;
Sui Fang
;
Wang Simeng
;
Su Xi
收藏
  |  
浏览/下载:9/0
  |  
提交时间:2019/11/26
hazard-free therapy
multitargeted cancer therapy
engineered protein
protein&minus
protein interactions
self-assembled protein-based nanoparticles
©版权所有 ©2017 CSpace - Powered by
CSpace